
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxNMDlIdUhMOFdkdjVMWTBYTjl5TWc4RnVqckpQdkpNRk9MMUd6SW1rb1BRaTFqOVB4dzNJVFRwZk9KRm9zU1E1SG9Eemx4S3drYkkzYXZZYmFpS1pETk9ZQmlTYlFPZnQ4M0xrYW5oT085cW5OTjBCbzJFVHBsZUpwcmo1NDFwcEcwTzRzZ2VUVS1QdUp2ZHVmczRoQWxvbXJrZkRfSVhkZWhTdVl3VjFRa3V5UkxBRVQzUjR0ZE9XamVtaFVITFMxQlFndkhvc0VfelhBcWdENHo0VzQ1dGZzY0kwNHJMejF1aVJjOVpSQXBvYWFwc1BRZjJsaFJ0UnJxUTR0dW1WRlBodWJCTFd3RXI5ZFVaSk9jZk9n?oc=5" target="_blank">Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)</a>&nbsp;&nbsp;<font color="#6f6f6f">Amgen</font>